ASLN
- ASLAN Pharmaceuticals Limited
()
Overview
Company Summary
ASLAN Pharmaceuticals Limited (ASLN) is a biopharmaceutical company that focuses on developing innovative drugs to address unmet medical needs in oncology and immunology. The company primarily operates in Asia, with its headquarters located in Singapore.
ASLAN Pharmaceuticals is dedicated to the discovery and development of novel therapeutics that can provide effective treatment options for patients suffering from various types of cancers. The company's research primarily revolves around identifying and targeting specific pathways and mechanisms within cancer cells to inhibit their growth and progression.
One of their key drug candidates is varlitinib, an oral, small molecule inhibitor that targets human epidermal growth factor receptor (EGFR) family members. This drug has shown promising results in clinical trials for gastric cancer and biliary tract cancer. ASLAN Pharmaceuticals is also developing other potential oncology therapies for different cancer types, such as acute myeloid leukemia (AML) and breast cancer.
In addition to their oncology pipeline, ASLAN Pharmaceuticals has also been working on developing immunology-focused drugs. The company aims to address significant diseases in this field by developing innovative therapeutics that modulate immune responses. Their immunology program is currently focused on developing a potential therapy for atopic dermatitis, a chronic inflammatory skin condition.
ASLAN Pharmaceuticals collaborates with academic institutions, research organizations, and pharmaceutical companies worldwide to accelerate the development of their drug candidates. They leverage cutting-edge scientific knowledge and expertise to advance their research programs and ultimately provide patients with more effective and targeted treatment options.
Overall, ASLAN Pharmaceuticals Limited strives to make a meaningful impact on patients' lives by developing innovative therapies for cancer and immunological diseases. Their focus on discovering and advancing novel drug candidates showcases their commitment to addressing unmet medical needs and improving patient outcomes.